Overview

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

Status:
Recruiting
Trial end date:
2025-08-29
Target enrollment:
Participant gender:
Summary
This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to participants at least 2 years of age with Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA)-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS).
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.